Full text access provided to Googlebot Access
Cases that were excluded from this study included: large-cell transformation from low-grade B-cell lymphoma, DLBCL associated with Epstein–Barr virus, immunodeficiency-associated lymphoproliferative disorders (especially human immunodeficiency virus ...
Nature.com - Fri, 26 Jun 2015 04:41



Breakthrough T-Cell Therapy Halts EBV-Associated Lymphoproliferative Disorders
Infusions of Epstein-Barr virus (EBV)–specific cytotoxic T lymphocytes (CTLs) from healthy donors led to high response rates and significant extensions in overall survival (OS) for patients with rituximab-refractory EBV–associated lymphoproliferative ...
OncLive - Sun, 19 Apr 2015 06:10

Large Granular Lymphocyte Leukaemia (LGLL)
LGLL is a rare lymphoproliferative disorder with signs and symptoms varying in severity between patients, but commonly including neutropenia, recurrent infections, anaemia, debilitating fatigue and an enlarged spleen. LGLL is also associated with ...
Leukaemia & Lymphoma Research - Thu, 04 Jun 2015 05:15

Increased risk of nephrolithiasis is associated with treatment of hematologic ...
The incidence of nephrolithiasis in a population of patients (over 1 300 patients with up to 10 years follow-up) with lymphoproliferative and myeloproliferative disorders was 5.5%. In multivariate analysis, we report that diabetes mellitus ...
UroToday - Tue, 16 Jun 2015 11:11

New guidelines address primary cutaneous T-cell lymphoproliferative disorders
HOLLYWOOD, FLA. – The treatment of patients with lymphomatoid papulosis depends on the presentation, according to new National Comprehensive Cancer Network guidelines for managing primary cutaneous CD30+ T-cell lymphoproliferative disorders.
The Oncology Report - Wed, 16 Apr 2014 13:19

Higher Rates of Lymphoproliferative Disorders in Patients with Celiac Disease
A team of researchers recently investigated rates of various lymphoproliferative disorders in patients with celiac disease. The research team included L.A. Leslie, B. Lebwohl, A.I. Neugut, J. Gregory Mears, G. Bhagat, and P.H. Green. They are ...
Celiac.com - Mon, 30 Jul 2012 00:18

Effect of Genzyme's Multiple Sclerosis Treatment Lemtrada® (alemtuzumab) on ...
The Phase III trials of Lemtrada were randomized, two-year pivotal studies comparing treatment with Lemtrada to high-dose subcutaneous interferon beta-1a (Rebif®) in patients with RRMS who had active disease and were either new to treatment (CARE-MS ...
MarketWatch - Thu, 23 Apr 2015 06:05



Weighing Risks and Rewards with Alemtuzumab in Patients with Multiple Sclerosis
Samuel F. Hunter, MD, PhD, president of the Advanced Neurosciences Institute in Franklin, Tennessee, gave a presentation on outcomes in patients with relapsing multiple sclerosis (MS) treated with Lemtrada (alemtuzumab) at the 2015 Annual Meeting of ...
MD Magazine - Sat, 30 May 2015 10:37


1  2  3  4  5  6  7  8    ->


We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.

Last update: September 2014